ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Fujifilm teams up with Bayer on cancer drug development

Companies to test cheaper stem cell-based immunotherapy drug for cancer patients

Japan's Fujifilm and Germany's Bayer are collaborating on tests that could make a promising cancer treatment more affordable.

TOKYO -- Fujifilm Holdings has joined hands with German drugmaker Bayer to develop an immune-based cancer treatment using induced pluripotent stem cells.

Currently, stem cell treatments are expensive and take time to prescribe. The Japan-German alliance intends to surmount these hurdles by using a new method in which iPS cells come from someone other than the patient. In the conventional method, cells from patients themselves are used.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more